Unlike PCR, the regions are amplified in E. coli, not in vitro, and thus are subject to review by the E. coli replication machinery. Both of these advances present new options for DNA engineering.

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

The vaccine, currently in phase 3 trials, targets extraintestinal pathogenic Escherichia coli or ‘ExPEC’, which is estimated to cause around 10 million cases of invasive disease every year and ...

The news of the day as interpreted by our talented artists, illustrators and cartoonists.

1. Description of cartoon 1.1. The first panel of the cartoon features the heading, “The boys who cried wolf”, next to portraits of Kallie Kriel of AfriForum and Dirk Hermann of Solidarity. It quotes ...